As of February 21st, Prof. Etienne Sokal, M.D., Ph.D., has stepped back from his operational role as Group CMO and will transition to the position of Chairman of Promethera®’s Scientific & Medical Advisory Board and Senior Scientific & Medical Advisor. The search for a successor is ongoing. The Company will present a new Group Chief Medical Officer in due time. In the meantime, William Macias, M.D., Ph.D. was appointed as interim CMO of Promethera®. Dr. Macias has supported the company as a clinical consultant since 2019. He is located in Indianapolis, IN, USA. Dr. Macias brings extensive experience to the organization from multiple roles at Eli Lilly and Company and as a strategic management and drug development consultant.

We sincerely thank Prof. Sokal, M.D., Ph.D. for his very substantial efforts over the last several years and his contributions to the scientific discoveries that led to the formation of Promethera®. We look forward to continuing our collaboration with him under the new framework and in his new senior advisory role to Promethera®” commented John Tchelingerian, Ph.D., President and CEO of the Promethera® Group.”


About Promethera® Biosciences.
Head office
Watson & Crick Hill - Rue Granbonpré 11, 1435 Mont-Saint-Guibert, Belgique
John Tchelingerian, PhD, President & CEO
Promethera® Biosciences is a global innovator in liver therapeutics whose mission is to bring patients life-saving treatments to reduce the need for liver transplantation. Promethera® develops and manufactures allogeneic cell-based medicines for liver diseases by using regenerative medicine technology.

More information: PROMETHERA